Oric Pharmaceuticals, Inc. (NASDAQ: ORIC)

Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to improving patients' lives by overcoming resistance in cancer. The company's management team and founders have a rich heritage in the oncology industry, having discovered and developed groundbreaking medicines at companies such as Ignyta, Medivation, Aragon, and Genentech.

Oric Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing innovative therapies that overcome resistance in cancer. The company's main business activities include discovering, developing, and commercializing innovative therapies that target key resistance mechanisms in cancer. Oric Pharmaceuticals operates in the United States and is expanding its portfolio of product candidates through internal research activities and business development efforts.

The company generates revenue through the development of its product candidates, which target innate resistance, acquired resistance, and bypass resistance. ORIC-114, ORIC-944, and ORIC-533 are the primary product candidates in Oric Pharmaceuticals' pipeline. ORIC-114 is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency towards exon 20 insertion mutations. ORIC-944 is a potent and selective allosteric inhibitor of PRC2 with a mechanism of action via binding the EED subunit. ORIC-533 is an orally bioavailable small molecule inhibitor of CD73, which controls the rate at which extracellular adenosine is produced.

Oric Pharmaceuticals' competitive advantage lies in its resistance platform, which focuses on three areas: innate resistance, acquired resistance, and bypass resistance. The company's pipeline includes several programs targeting key tumor dependencies, including hormone-dependent cancers, precision oncology, and key tumor dependencies. Oric Pharmaceuticals' strategy is to leverage its resistance platform to build a leading, fully integrated company focused on delivering innovative medicines that aim to overcome resistance in cancer.

Oric Pharmaceuticals has entered into several license agreements, including the Voronoi License Agreement and the Mirati License Agreement. Under these agreements, Oric Pharmaceuticals has obtained a worldwide, exclusive, sublicensable, royalty-free license under certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how.

In terms of sales and marketing, Oric Pharmaceuticals intends to retain significant development and commercial rights to its product candidates and, if marketing approval is obtained, to commercialize its product candidates on its own, or potentially with a partner, in the United States and other regions. The company currently has no sales, marketing, or commercial product distribution capabilities, but intends to build the necessary infrastructure and capabilities over time.

In terms of manufacturing, Oric Pharmaceuticals does not own or operate, and currently has no plans to establish, any manufacturing facilities. The company relies on third parties for the manufacture of its product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of its product candidates obtain marketing approval.

Oric Pharmaceuticals' patent portfolio consists of issued patents and pending patent applications that it owns or in-licensed related to ORIC-114, ORIC-944, ORIC-533, and various other compounds and programs. The company strives to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to its business, including obtaining, maintaining, and defending its patent rights.